Discovery and validation of novel biomarkers of drug response in metastatic colon cancer.

结直肠癌是澳大利亚癌症相关死亡的第三大原因。虽然现在结肠癌患者有许多治疗选择，但患者对个别药物的反应存在显着差异。该NHMRC项目赠款将寻求确定预测患者对特定治疗反应的可能性的遗传标记。这将使个别患者能够使用最有可能对其有益的药物进行治疗。

Colorectal cancer is the third leading cause of cancer related death in Australia. While there are now a number of treatment options for patients with colon cancer, there is significant variability in response among patients to individual drugs. This NHMRC project grant will seek to identify genetic markers which predict the likelihood of a patient responding to a specific therapy. This will enable individual patients to be treated with the drug most likely to be of benefit to them.